320 results about "Prolonged-release tablet" patented technology

The present invention discloses a slowly-released oral medicine preparation which is made up by using breviscapine as main raw material and has the functions of promoting blood circulation and removing blood stasis, removing obstruction in the channels to relieve pain for curing angiocardiopathy and cerebrovascular disease with obvious therapeutic effect and its preparation method. Said slowly-released tablet (by one tablet) contains 60-120 mg of breviscapine, 20-75 mg of diluent, 50-150 mg of filling agent and 10-50 mg of slow release material. Said invention also provides its preparation method and concrete steps.

The invention relates to a double-layer sustained release tablet for supplementing iron, the double-layer sustained release tablet consists of a sustained release layer and a quick release layer laminating with each other at the weight ratio of 1:0.25-1:4; the sustained release layer consists of an iron-containing compound, a sustained release framework, an adhesive, a lubricant and a filler; the quick release layer consists of a traditional Chinese medicine for enriching the blood and/or invigorating vital energy, a filler, a disintegrating agent, an adhesive and a lubricant; the quick release layer can also be added with vitamins. In the double-layer sustained release tablet, by arranging the iron-containing compound in the sustained release layer and the traditional Chinese medicine in the quick release layer, the iron element is released slowly and uniformly, which increases the absorption rate, avoids gastrointestinal reaction caused by high-content iron; meanwhile the double-layer sustained release tablet supplements iron element and the traditional Chinese medicine which has the functions of enriching the blood and invigorating vital energy, thus fully improving the nutritional status caused by iron deficiency anemia and improving iron supplementing effect.

The invention provides a preparation method of an edoxaban sustained release matrix tablet. The specific prescription of the edoxaban sustained release tablet consists of the following components in percentage by weight: 14-21 percent of edoxaban p-toluene sulfonate hydrate, 0-36 percent of hydroxypropyl methylcellulose, 0-28 percent of carbomer, 10-28 percent of lactose, 29-38 percent of diluent, 0-3 percent of povidone and 0.6-4 percent of lubricant.

The invention relates to a medicinal composition containing ibuprofen sodium salt, which is prepared by taking ibuprofen sodium salt and other one or a plurality of medicinal components as active ingredients, and combing the active ingredients with pharmaceutically appropriate auxiliary materials. The medicinal composition can be made into oral preparations, including conventional tablets, dispersible tablets, sustained release tablets, capsules, sustained release capsules, soft capsules, particles, dry suspension, suspension and the like, and used for symptomatic treatment of being antipyretic, antiphlogistic, analgesic and anti-allergic, and improving sleeping.

The invention relates to a nifedipine sustained release tablet and a preparation method thereof. The nifedipine sustained release tablet is characterized by comprising a tablet core and film coating liquid, wherein the tablet core comprises the following components in percentage by mass: 10 to 12 percent of nifedipine (Nif), 6.5 to 7.5 percent of hydroxypropyl methyl cellulose K4M, 45 to 47 percent of lactose, 34 to 35 percent of microcrystalline cellulose, 0.48 to 0.55 percent of lauryl sodium sulfate, a proper amount of 95 percent ethanol and a proper amount of magnesium stearate; and the film coating liquid comprises the following component in percentage by mass: 5.85 to 6.55 percent of Opadry II and 92.86 to 93.82 percent of distilled water. The preparation method comprises the following step of: mixing the nifedipine and polymer by utilizing the imported polymer and dispersion technology to form a hydrophilic matrix tablet so as to fulfill the aim of sustained release. Compared with an ordinary tablet, the sustained release tablet can continuously act for 12 hours relaxatively, is released in a sustained way and has less and slighter adverse reaction.

A method for producing a sustained-release tablet having improved stability and content uniformity is provided. The method involves first preparing a core tablet by granulating, drying, milling, blending, and compressing a mixture of active and inactive ingredients. Four coating layers are applied to the core tablet: an inner layer, an enteric coating layer, an active layer, and an outer layer. The active ingredient may be a tetracycline, such as doxycycline. A sustained-release tablet prepared according to the method is also described.

The invention discloses an immunomodulator slow-release preparation and a preparation method thereof. A lenalidomide slow-release tablet is composed of a slow-release layer and an optional quick-release layer, wherein the slow-release layer contains active ingredients of lenalidomide and a slow-release framework material simultaneously; the quick-release layer does not contain the slow-release framework material. The lenalidomide slow-release tablet disclosed by the invention is capable of slowly and uniformly releasing medicines by virtue of the slow-release framework material, so as to reduce the release speed, delay the time to peak, prolong the action time of lenalidomide, and provide a uniform and constant blood concentration. Moreover, The lenalidomide slow-release tablet disclosed by the invention is simple in prescription and excellent in quality stability; the preparation process is simple to operate, free from special treatment and production equipment, low in production cost, and beneficial to batch-enlarged industrial production for the product; the preparation method is high in yield, the granulation and crushing procedures are simple and practicable to operate, the intermediate material is good in stability, flowability, compressibility and content uniformity, and completely meets the requirements of tabletting, and the surface of the prepared tablet is smooth and beautiful.

The invention relates to a sustained release tablet dosage, in particular to a Tacrolimus sustained release tablet used for liver and kidney transplantation patients and a preparation method thereof, belonging to the field of medicine technology. The invention is characterized in that Tacrolimus and adhesive are taken and dissolved in ethanol to prepare Tacrolimus solution; sustained release materials, thinner and flow agent are taken, mixed and dispersed uniformly and then added into the Tacrolimus solution to prepare wet particles, which are dried, ground and added and mixed with lubricant; finally, the Tacrolimus sustained release tablet is prepared after tabletting and drying. The sustained release tablet has the unique advantages of: reducing administration times, improving the administration adaptability of patients; after administration, having stable blood concentration, small toxic and side effects and improving the drug effect and safety; reducing the total dosage of drugs so as to achieve the greatest curative effect by the lowest dosage; being capable of being realized on most of tablet production lines and easily accepted by manufacturing units and manufacturers due to relatively simple preparation process; and having relatively low manufacturing cost and broad clinical application prospect.

This invention concerns a the maleic acid trimebutine sustained-releasing tablets with rapid releasing part and preparation of pharmaceutical pharmaceuticals, including double slice and tablet mixed and suppressed by particles with different releasing characteristics, it is found in the invention that after the maleic acid trimebutine and fumaric acid being mixed and granulated, the stability and compressibility of the maleic acid trimebutine is improved, and its citation moist is lowered, and it can be used for preparation of the praeparatum of the present invention, the present invention includes the rapid releasing part and sustained-releasing part.

The invention relates to an isosorbide mononitrate sustained-release tablet and a preparation method thereof, belonging to the technical field of medicinal preparations. The sustained-release tablet comprises a coating of isosorbide mononitrate drug loaded microballoons which account for 48% to 55% of the total weight of the tablet and a quick-release layer which accounts for 45% to 52% and comprises isosorbide mononitrate, a binder, a filler and a lubricant. According to the invention, isosorbide mononitrate is divided into two parts, i.e., the part of quick release and the part of sustained release, which enables the tablet to take effect rapidly at an initial stage of administration, maintain an effective plasma concentration after the effective plasma concentration is reached and retain the effective plasma concentration at a low level so as to reduce residual quantity of the tablet at administration time of the tablet the next day, thereby effectively avoiding generation of drug resistance.

The invention provides a multicomponent sustained-release preparation and a preparation method thereof. An isolation layer is arranged between a sustained-release part and a quick release part in the sustained-release preparation to effectively isolate the interaction of a sustained-release tablet core and an external quick release coat, the external quick release part is quickly released completely, the isolation layer is quickly dissolved when meeting an aqueous medium, and the release of the sustained-release tablet core is not influenced. The technology can be applied to compound sustained-release preparations as required.

The present invention relates to an oral medicine preparation for curing intestinal irritability syndrome using constipatino as main sympton-tijaseluo maleate. It is made up by using tijaseluo maleate as active component and adding proper auxiliary material through a certain preparation process, and can be made into various oral dosage forms of tablet, oral disintegrant table, effervescent tablet, capsule, suspension gel and powder preparation, etc.

The invention provides a preparation method of double-layer sustained release tablets containing folic acid, calcium carbonate, vitamin B12 and vitamin B6, and the combination is a double-layered tablet, wherein, vitamin B6 is a slow release layer and the folic acid is a quick release layer. In the method, vitamin B6 is prepared into the slow release layer and the folic acid and the like are prepared into the quick release layer, and then the two layers are pressed into the double-layered tablets. The method solves the common problem of splinters owing to long-time placement of the double-layered tablets; and the prepared compound vitamin B6 sustained release tablets has good appearance, tight combination between an upper layer and a lower layer, wherein, the swelling rate and the swelling degree of the two layers are consistent under the influence of the external humiture, which can always maintain good appearance and release speed. The compound vitamin B6 sustained release tablets have simple preparation method, available raw materials, applicability to large-scale industrial production and good application prospect.

The invention provides an epalrestat slow-release tablet and a preparation method thereof. The slow-release tablet is prepared from the following components in parts by weight: 1-40 parts of epalrestat, 5-60 parts of slow-release material, 0-90 parts of filler, 0.1-2 parts of lubricant and right amount of adhesive. The slow-release material comprises hydroxypropyl methylcellulose or a mixture of hydroxypropyl methylcellulose and ethyl cellulose. The preparation method comprises the following steps: evenly mixing the epalrestat, slow-release material and filler according to the prescription amounts, adding the adhesive to obtain a soft material, granulating the soft material, drying, finishing, adding the lubricant, and tabletting. Compared with the conventional oral epalrestat common preparation, the epalrestat slow-release tablet provided by the invention can smoothly and slowly release the medicines after being orally dosed, and can maintain therapeutic action for a longer time.

The invention relates to a indapamide retard tablet and its preparation process, said retard tablet comprising indapamide, bone material, filler and lubricant, in each said tablet containing controllable 0.5-1.5mg( each tablet containing 0.15 g. or 150g/1000 tablet ).

The invention provides a method for preparing a divalproex sodium-containing sustained-release tablet for treating epilepsy. The sustained-release tablet contains divalproex sodium, a sustained-release material, a binder and a lubricant. The preparation method comprises the following steps of: mixing the divalproex sodium and the sustained-release material to obtain a mixture, adding the binder for wet granulation, drying, granulating, adding into other uniformly mixed auxiliary materials, and tabletting to obtain the divalproex sodium-containing sustained-release tablet. The sustained-release tablet can be sustainedly released for 24 hours, and is good in appearance, stable in performance and convenient to take.

The invention discloses a drug composition containing sitagliptin and melbine. A melbine sustained release tablet core is coated with sitagliptin in a mixed suspension mode. The invention also discloses composition of a sitagliptin suspension. By carefully selecting preparation prescriptions, antioxidants are not used in the prescriptions, a production process is simple, and meanwhile and the technical advantages of uniform preparation content, consistent dissolution, good stability and the like are also achieved.

A slow-releasing aspirin table for treating acute ischemic apoplexy and cerebrovascular and cardiovascular diseases is prepared from aspirin and auxiliaries through proportionally mixing hydroxypropyl methylcellulose, polyacrylic resin II and aspirin, mixing with the solution of hydroxypropyl methylcellulose in alcohol to obtain soft material, granulating by nylon sieve, drying, and loading in capsules, or further mixing with talc powder and tabletting. Its advantages are stable concentration in blood and durable curative effect.

The invention discloses isosorbide mononitrate sustained release tablets and a preparation process thereof. According to the preparation, the sustained release aim is achieved by adopting a method for combining mesoporous carbon and membrane controlled coating. The process comprises the following steps: preparing a mesoporous carbon-isosorbide mononitrate complex; by taking ethyl cellulose as a sustained release coating material and taking hydroxyethyl cellulose as a pore-foaming agent, performing bottom-spray coating by adopting a fluidized bed to obtain sustained release coated pills; and mixing the pills with other pharmaceutically acceptable auxiliary materials, and pressing into the tablets. The sustained release tablets disclosed by the invention have the advantages that the drug release is stable, membrane aging is avoided in the storage process, the drug release stability is high, the bioavailability is high, and the preparation process is simple.

The present invention relates to a pharmaceutical composition containing a statin in the form of a zinc salt. It is an oral preparation made of zinc salts of statins and a calcium ion antagonist as the active pharmaceutical ingredients and pharmaceutically acceptable pharmaceutical excipients, including granules, ordinary tablets, chewable tablets, dispersible tablets, Orally disintegrating tablets, buccal tablets, capsules, dropping pills, sustained-release tablets, etc. As a new preparation for the treatment and prevention of various hypertension and hyperlipidemia, the preparation is widely used clinically.

The invention relates to a lovastatin and niacin sustained-release tablet used for reducing blood lipid and the preparation method thereof; each tablet contains 500mg of niacin and 20 mg of lovastatin. The coating form is adopted for preparation; the niacin is used as the core of the sustained-release tablet; lovastatin is dissolved in coating liquid to be used as quick release part. The lovastatin and niacin sustained-release tablet used for reducing blood lipid and the preparation method have the advantages of simple and practical preparation process, low cost, enabling the medicine release to accord with the national pharmacopoeia and the treatment requirements, well improving the clinical symptoms, reducing side effects and providing a blood-reducing medicine with low price.

The invention provides a bezafibrate sustained release tablet, comprising a sustained release tablet core and a film coated on the tablet core. The bezafibrate sustained release tablet comprises, by weight, 400 parts of bezafibrate, 60-120 parts of skeletal material and 50-150 parts of accessory facilitating release of drug; and the coating film accounts for 1-5wt% of the tablet. The bezafibrate sustained release tablet of the invention can effectively adjust release rate of the medicament and obtain stationary and lasting effective plasma concentration, so as to reduce side-effect and drug administration frequency; and absorption of medicament is not influenced by food intake and internal environment, so as to increase compliance of a patient. Therefore, the bezafibrate sustained release tablet can be widely applied to prevention and treatment of disease like hyperlipidemia.